SEC
CRNX icon

Seven Eight Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Seven Eight Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,150
Closed -$365K – 748
2024
Q2 		$365K Sell
8,150
-12,360
-60% -$571K 0.04% 575
2024
Q1 		$960K Sell
20,510
-14,402
-41% -$564K 0.1% 304
2023
Q4 		$1.24M Buy
+34,912
New +$1.07M 0.14% 208

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Seven Eight Capital's CRNX Position: Q3 2024 in Review

Seven Eight Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2024, closing a stake of 8,150 shares — an estimated $365K sold.

Seven Eight Capital first reported a position in CRNX in Q4 2023 and held it in 3 quarters. The position peaked at $1.24M in Q4 2023. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

  • Seven Eight Capital reported no remaining Crinetics Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Seven Eight Capital sold 8,150 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $365K.
  • Seven Eight Capital first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Seven Eight Capital's Crinetics Pharmaceuticals position peaked at $1.24M in Q4 2023.
  • 235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.